TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21641515

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) treatment (Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Western Medicine (WM) treatment (diclofenec, methotrexate and sulfasalazine)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Western Medicine (WM) treatment
Number of subjects: 170

Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 170
Study: 18359425

Group type: EXPERIMENTAL
Intervention: Targeted antibiotic therapy (TT)
Number of subjects: 740

Group type: COMPARATOR
Intervention: No targeted therapy (NoTT)
Number of subjects: 740
Study: 16509530

Group type: EXPERIMENTAL
Intervention: Daily comprehensive muscle training programme (4-10 minutes daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (12 matched children with PWS)
Number of subjects: 11
Study: 14623660

Group type: EXPERIMENTAL
Intervention: Aircast brace
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bledsoe brace
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Swede-O brace
Number of subjects: 14

Group type: COMPARATOR
Intervention: No-brace
Number of subjects: 14
Study: 11009231

Group type: EXPERIMENTAL
Intervention: Mexiletine (maximum dose of 1,350 mg/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9112363

Group type: EXPERIMENTAL
Intervention: Isradipine (0.005 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 30
Study: 8495257

Group type: EXPERIMENTAL
Intervention: Pyritinol (PY) 600 mg/day for 1 year
Number of subjects: 281

Group type: COMPARATOR
Intervention: Auranofin (AU) 6 mg/day for 1 year
Number of subjects: 281
Study: 3632393

Group type: EXPERIMENTAL
Intervention: High-dose prednisone therapy (1.5 mg/kg daily, max 80 mg for six months)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Natural history controls
Number of subjects: 33
Study: 31913207

Group type: EXPERIMENTAL
Intervention: Isolated congenital myogenic ptosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Aponeurotic ptosis
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 29048754

Group type: EXPERIMENTAL
Intervention: Endometrial scratch (n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (n=150)
Number of subjects: 300
Study: 27030352

Group type: EXPERIMENTAL
Intervention: Registered Dietitian Group (RDG)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 81
Study: 25634801

Group type: EXPERIMENTAL
Intervention: WBRT + sodium nitrite (267 µg/kg/h for 2 hours before each radiation fraction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 20
Study: 23340564

Group type: EXPERIMENTAL
Intervention: HibMenCY x 4
Number of subjects: 0

Group type: COMPARATOR
Intervention: HibMenCY x 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hib
Number of subjects: 0
Study: 21211975

Group type: EXPERIMENTAL
Intervention: De Marco Formula (DMF) combined with conventional therapy (0, 15 ml/kg day i.m. for 10 days, then twice a week until healing or 52 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 47
Study: 18264992

Group type: EXPERIMENTAL
Intervention: Test procedure for treatment effects among compliers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size calculation formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parameters affecting sample size
Number of subjects: 0
Study: 16945139

Group type: EXPERIMENTAL
Intervention: High-tech veteran (trained echocardiologist using full feature echocardiographic platform)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-tech beginner (echocardiographer with limited training using hand-held echocardiography)
Number of subjects: 20
Study: 14513439

Group type: EXPERIMENTAL
Intervention: 500 cGy radiation treatment (group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1,000 cGy radiation treatment (group B)
Number of subjects: 0
Study: 10714094

Group type: EXPERIMENTAL
Intervention: ecNOS gene polymorphism (aa, ab, bb genotypes) in AMI patients
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: ecNOS gene polymorphism (aa, ab, bb genotypes) in AMI patients below age 51
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Smoking status in young AMI patients
Number of subjects: 121

Group type: COMPARATOR
Intervention: Incidence of hypertension and diabetes mellitus
Number of subjects: 121
Study: 9184614

Group type: EXPERIMENTAL
Intervention: Olanzapine (5 to 20 mg/day)
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Haloperidol (5 to 20 mg/day)
Number of subjects: 2606
Study: 8241668

Group type: EXPERIMENTAL
Intervention: Zinc-fortified formula
Number of subjects: 39

Group type: COMPARATOR
Intervention: Unfortified formula
Number of subjects: 39
Study: 3901209

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gentamicin/clindamycin
Number of subjects: 0
Study: 29636089

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Tripterygium wilfordii Hook F (TwHF)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Methotrexate + Tripterygium wilfordii Hook F (MTX + TwHF)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tripterygium wilfordii Hook F + Methotrexate (MTX + TwHF)
Number of subjects: 207
Study: 27884147

Group type: EXPERIMENTAL
Intervention: Standard cardiac rehabilitation programme + four osteopathic treatments (OT) at weeks 4, 5, 8, and 12 after surgery.
Number of subjects: 308

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation programme.
Number of subjects: 308
Study: 25139208

Group type: EXPERIMENTAL
Intervention: FUTURE I/II criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PATRICIA criteria
Number of subjects: 0
Study: 24261985

Group type: EXPERIMENTAL
Intervention: Multi-faceted workplace intervention consisting of participatory ergonomics, physical training, and cognitive behavioral training
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 4
Study: 20550764

Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT) with a 24-h delay in incubation
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: QuantiFERON®-TB Gold In-Tube test (QFT-GIT) during power outages
Number of subjects: 109
Study: 18071011

Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 160 microg daily for 3 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inhaled ciclesonide 320 microg daily for 3 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled ciclesonide 40 microg daily for 3 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Inhaled ciclesonide 80 microg daily for 3 weeks
Number of subjects: 26
Study: 16011141

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 114
Study: 14697160

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam (4 g/8 h iv)
Number of subjects: 150

Group type: COMPARATOR
Intervention: ceftriaxone (2 g/24 h iv) plus ornidazole (1 g/24 h iv)
Number of subjects: 150
Study: 10579472

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (500 mg) plus ketoconazole (100 mg twice daily for 3 days)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quinine hydrochloride (500 mg) plus fluvoxamine (25 mg twice daily for 2 days)
Number of subjects: 9
Study: 8619360

Group type: EXPERIMENTAL
Intervention: iobitridol 350
Number of subjects: 40

Group type: COMPARATOR
Intervention: iopamidol 370
Number of subjects: 40
Study: 2047064

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (25-mg tablets orally every 8 hours for 72 hours)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (same regimen as vitamin B6)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 572996

Group type: EXPERIMENTAL
Intervention: Soy feed
Number of subjects: 40

Group type: COMPARATOR
Intervention: Humanized cow's milk formula
Number of subjects: 40
Study: 30179928

Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 164

Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 164
Study: 27338807

Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5 to 75 mg) administered for 14 consecutive nights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lemborexant (2.5, 10, or 25 mg) administered for 14 consecutive nights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered for 14 consecutive nights
Number of subjects: 0
Study: 26637091

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity test (BRS) in supine position (L-BRS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity test (BRS) in standing position (S-BRS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baroreflex sensitivity test (BRS)
Number of subjects: 60
Study: 23711230

Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Volume-cycled ventilation (VCV)
Number of subjects: 48
Study: 20537347

Group type: EXPERIMENTAL
Intervention: P duration greater than 110 milliseconds
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Other ECG parameters (P to PR segment ratio, P terminal force in lead V1, P wave area, bifid, and biphasic P wave)
Number of subjects: 339
Study: 20110022

Group type: EXPERIMENTAL
Intervention: Atorvastatin/Fenofibrate FDC (40 mg/100 mg)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Fenofibrate 145 mg
Number of subjects: 220
Study: 16396872

Group type: EXPERIMENTAL
Intervention: Comprehensive education and home visiting for families of children with BLLs 15 to 19 microg/dL
Number of subjects: 175

Group type: COMPARATOR
Intervention: Customary care (1 or 2 educational visits)
Number of subjects: 175
Study: 15623686

Group type: EXPERIMENTAL
Intervention: 0.5 mg CAB once daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 1.0 mg CAB once daily
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 2.0 mg CAB once daily
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: CAB therapy (mean dose of 2.2 mg per day over 1 year)
Number of subjects: 85
Study: 11242379

Group type: EXPERIMENTAL
Intervention: Surgical treatment with distraction and fusion using Harrington rods
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Brace treatment
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (100 age- and gender-matched individuals)
Number of subjects: 283
Study: 9260078

Group type: EXPERIMENTAL
Intervention: Cola at 33 mg/serving
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Coffee at 33 mg/serving
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cola at 100 mg/serving
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Coffee at 100 mg/serving
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (both cola and coffee)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noncaffeinated beverages
Number of subjects: 11
Study: 8501457

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Buprenorphine 6 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methadone 35 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Methadone 65 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 125
Study: 3551621

Group type: EXPERIMENTAL
Intervention: ROM Dance Program (experimental group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (traditional exercise and rest regimens)
Number of subjects: 33
Study: 28624647

Group type: EXPERIMENTAL
Intervention: FNA
Number of subjects: 274

Group type: COMPARATOR
Intervention: FNB
Number of subjects: 274
Study: 27740603

Group type: EXPERIMENTAL
Intervention: Aronia-citrus juice
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 16
Study: 23767786

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral smoking intervention with AS reduction component
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard cognitive behavioral smoking intervention
Number of subjects: 169
Study: 24355229

Group type: EXPERIMENTAL
Intervention: Inhaled crenotherapy with salso-sulphide water
Number of subjects: 107

Group type: COMPARATOR
Intervention: Isotonic saline (NaCl 0.9 percent)
Number of subjects: 107
Study: 20494043

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 4326

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4326
Study: 18003666

Group type: EXPERIMENTAL
Intervention: Combination of folic acid (2.5 mg), vitamin B6 (50 mg), and vitamin B12 (1 mg) daily for 5 years
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Combination of folic acid, vitamin B6, and vitamin B12
Number of subjects: 619
Study: 15910349

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.2 mg.kg‐1 bolus followed by 5 microg.kg‐1.min‐1 infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline infusion)
Number of subjects: 30
Study: 12909221

Group type: EXPERIMENTAL
Intervention: GEM CCRT (600 mg/m(2)/wk for 6 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 5-FU CCRT (500 mg/m(2)/d for 3 days repeated every 2 weeks for 6 weeks)
Number of subjects: 34
Study: 10745429

Group type: EXPERIMENTAL
Intervention: Iomeprol 350
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iopentol 350
Number of subjects: 20
Study: 8886549

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 2037068

Group type: EXPERIMENTAL
Intervention: Chimaeric protein SP1-Kox 29
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized oligonucleotides (GGG NNNN GGC)
Number of subjects: 0
Study: 6132082

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (50‐200 micrograms/kg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous frusemide (1 mg/kg)
Number of subjects: 28
Study: 31931250

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg slow pumping dose, maintained at 0.3 μg/kg·h intraoperatively)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Saline infusion (same amount as dexmedetomidine, same infusion method)
Number of subjects: 88
Study: 30851250

Group type: EXPERIMENTAL
Intervention: Immediate implant placement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed implant placement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall implant survival
Number of subjects: 20
Study: 29410607

Group type: EXPERIMENTAL
Intervention: Music intervention (MTSZ) group, received a 1-month music intervention series combined with antipsychotic drugs
Number of subjects: 36

Group type: COMPARATOR
Intervention: No-music intervention (UMTSZ) group, treated solely with antipsychotic drugs
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Music intervention (MTSZ) group
Number of subjects: 36
Study: 25500685

Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg/day
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1133
Study: 23348009

Group type: EXPERIMENTAL
Intervention: Pregnenolone (400 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21081550

Group type: EXPERIMENTAL
Intervention: varespladib methyl 500 mg once daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: varespladib methyl 250 mg once daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 135
Study: 19398260

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 576

Group type: COMPARATOR
Intervention: Open myomectomy
Number of subjects: 576
Study: 16189179

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 7

Group type: COMPARATOR
Intervention: l-arginine/GHRP-2
Number of subjects: 7

Group type: COMPARATOR
Intervention: GHRH/GHRP-2
Number of subjects: 7

Group type: COMPARATOR
Intervention: l-arginine/GHRH
Number of subjects: 7
Study: 12574185

Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transdermal estradiol (patch delivering 50 microg/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 10562937

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 90 mmHg
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 85 mmHg
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Target diastolic blood pressure < or = 80 mmHg
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 806
Study: 8889112

Group type: EXPERIMENTAL
Intervention: Exercise therapy (group 1, n = 27)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Exercise therapy (group 2, n = 34)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (group 3, n = 31)
Number of subjects: 92
Study: 1984327

Group type: EXPERIMENTAL
Intervention: Biphasic radiography
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopy
Number of subjects: 385
Study: 6339923

Group type: EXPERIMENTAL
Intervention: Acyclovir (200 mg per dose) five times daily for 10 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 48
Study: 30503296

Group type: EXPERIMENTAL
Intervention: Helical IMRT-based stereotactic body radiotherapy (SBRT) at dose levels 3-4 (42-60 Gy)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Helical IMRT-based stereotactic body radiotherapy (SBRT)
Number of subjects: 32
Study: 29777744

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 26573754

Group type: EXPERIMENTAL
Intervention: Intervention arm A (workshop + audit report)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention arm B (workshop + audit report + delayed prescribing evidence)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25131735

Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (NVAS)
Number of subjects: 5141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5141
Study: 22260307

Group type: EXPERIMENTAL
Intervention: Anterior suspension and posterior reconstruction during RALP (group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard RALP (group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 19499849

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg/die and gamma-linolenic acid (GLA) 360 mg/die
Number of subjects: 112

Group type: COMPARATOR
Intervention: Multivitamin B preparation (Vit B6 150 mg, Vit B1 100 mg, Vit B12 500 microg daily)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) and gamma-linolenic acid (GLA)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Multivitamin B preparation
Number of subjects: 112
Study: 17952842

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16366763

Group type: EXPERIMENTAL
Intervention: Cocaine (100 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cocaine (200 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cocaine (0 mg)
Number of subjects: 14
Study: 12169865

Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 400 mg
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg or 400 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 9459382

Group type: EXPERIMENTAL
Intervention: RS2 (uncooked high‐amylose cornstarch)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RS3 (extruded and retrograded high‐amylose cornstarch)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose (control)
Number of subjects: 24
Study: 8641325

Group type: EXPERIMENTAL
Intervention: Buffered sublingual captopril (pH 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unbuffered sublingual captopril
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Buffered and unbuffered sublingual captopril
Number of subjects: 14
Study: 2354483

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sustained-release verapamil
Number of subjects: 113
Study: 345586

Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride (Ditropan)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31142196

Group type: EXPERIMENTAL
Intervention: Learning an individualized song
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-training period
Number of subjects: 12
Study: 29110707

Group type: EXPERIMENTAL
Intervention: Multi-level intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25840296

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical anesthesia associated with cryoanalgesia
Number of subjects: 25
Study: 23903997

Group type: EXPERIMENTAL
Intervention: DDD patients
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DLS patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 20